WO2002001952A1 - Fluide de preservation pour cellules et tissus - Google Patents

Fluide de preservation pour cellules et tissus Download PDF

Info

Publication number
WO2002001952A1
WO2002001952A1 PCT/JP2001/005509 JP0105509W WO0201952A1 WO 2002001952 A1 WO2002001952 A1 WO 2002001952A1 JP 0105509 W JP0105509 W JP 0105509W WO 0201952 A1 WO0201952 A1 WO 0201952A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
preservation solution
cells
solution
polyphenol
Prior art date
Application number
PCT/JP2001/005509
Other languages
English (en)
Japanese (ja)
Inventor
Hiromi Wada
Kenji Ohnaka
Original Assignee
Hiromi Wada
Kenji Ohnaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiromi Wada, Kenji Ohnaka filed Critical Hiromi Wada
Priority to AU2001267836A priority Critical patent/AU2001267836A1/en
Priority to JP2002506588A priority patent/JP4908718B2/ja
Publication of WO2002001952A1 publication Critical patent/WO2002001952A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts

Definitions

  • the present invention relates to a liquid for preserving cells and preserving organs, limbs, skin and other tissues.
  • Euro-cold liquid is a solution containing potassium chloride, potassium dihydrogen phosphate, dicalcium hydrogen phosphate, sodium hydrogen carbonate and glucose.
  • this preservation solution can be used for kidneys that have high function retention, it does not provide sufficient protection for organs such as the lungs, and has a short function maintenance period.
  • It is a solution containing sodium, rafinose, and hydroxethyl starch as a colloid osmotic agent, and also contains adenosine and insulin. With this preservation solution, the protective effect is increased and the function maintenance period is prolonged, but it is pharmaceutically unstable.
  • An object of the present invention is to provide a cell / tissue preservation solution that has a better protective effect than conventional preservation solutions and can maintain its structure and function for a long period of time. Disclosure of the invention
  • the present inventors were able to complete the cell / tissue preservation solution of the present invention containing polyphenol as an active ingredient. Since polyphenol has an antioxidant effect, the preservation solution of the present invention has a high protective effect on cells and tissues. Therefore, according to the preservation solution of the present invention, the structure and function of cells and tissues can be maintained for a long period of time.
  • examples of polyphenols include catechin, epicatechin, gallocatechin, pigallocatechin, rutin, chromogen, kercetin, anthocyanin, flavonoid and the like. These compounds can be extracted from plants such as tea, buckwheat, coffee, evening onion, and purple potato. Further, these compounds may be chemically synthesized.
  • the preferred concentration of polyphenol is from 0.01 mM to 2000 mM, more preferably from 0.1 mM to 200 mM, particularly preferably from 0.1 mM to 10 mM, cells and tissues.
  • the preservation solution of the present invention may contain trehalose.
  • Trehalose includes ⁇ ;, ⁇ -trehalose, HI, ⁇ -trehalose, and] 3, j3-trehalose, and any of them may be used.
  • ⁇ ,,-trehaus is used.
  • Preferred trehalose concentrations are from 50 mM to 240 mM.
  • the osmotic pressure is preferably in the range of 270 to 450 ⁇ sm / 1 in order to prevent cells and tissues from expanding or contracting during storage. Further, in order to prevent acid degradation of the cells, it is desirable that the pH is in the range of 7-8. In order to keep the osmotic pressure and pH of the storage solution of the present invention within these ranges, it is preferable to add an appropriate osmotic agent or electrolyte.
  • Osmotic agents include collagen osmotic agents such as hydroxyxethyl starch and dextran starch.
  • the hydroxyxethyl starch preferably has a degree of substitution in the range of 0.4 to 0.8 and an average molecular weight of 2000 to 900, and more preferably an average molecular weight of 3 to 900. It is from 5,000 to 800,000.
  • the electrolyte may be a sodium or potassium salt of an organic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium dihydrogen phosphate, dihydrogen phosphate. Examples thereof include lithium, sodium hydrogen phosphate, sodium potassium hydrogen phosphate, sodium hydrogen carbonate, potassium hydrogen carbonate and sodium carbonate.
  • Organic acids include dalconic acid, lactic acid, acetic acid, propionic acid, / 3-hydroxybutyric acid and cunic acid.
  • the preferred composition of the preservation solution of the present invention is as follows.
  • the more preferred composition of the preservation solution of the present invention is as follows.
  • M g ++ and Ca ⁇ + may be contained in an amount of 1 to 1 O mM each.
  • other additives such as cell activators such as AT'P, vasodilators such as prostaglandins, and antibiotics can be added.
  • cell activators such as AT'P
  • vasodilators such as prostaglandins
  • antibiotics it is desirable not to add unstable compounds such as insulin in order to stabilize the formulation.
  • the method of using the preservation solution of the present invention is not particularly limited. For example, cells or tissues may be immersed in the preservation solution of the present invention and stored at a low temperature or frozen.
  • Example 1 solution The organ protection effect of the preservation solution obtained in Example 1 (Example 1 solution) was examined using the following rat lung extracorporeal perfusion model.
  • a preservation solution (ET-Kyoto solution) and an euro-colin solution prepared in the same manner as in Example 1 except that catechin was not added were similarly examined.
  • 30 male Lewis rats (weighing 300 g to 350 g) were randomly divided into three groups (groups I, II, and III), each with 10 rats. ET-Kyoto solution was used for the group I, Example 1 solution was used for the group II, and gulp-cold solution was used for the group 111.
  • a rat is placed in an air-collecting bottle containing 3 m 1 of enfluran (sold by Dainippon Pharmaceutical Co., Ltd., trade name: ET-REN (registered trademark)), and the rat is inhaled and anesthetized. 1 ml was injected intraperitoneally. The trachea was incised, the force was introduced, and the ventilator was connected and ventilated. After laparotomy and thoracotomy, 0.3 ml of heparin was injected into the peritoneal vena cava.
  • enfluran sold by Dainippon Pharmaceutical Co., Ltd., trade name: ET-REN (registered trademark)
  • the extracted cardiopulmonary block was immersed in a Petri dish containing a preservation solution, and stored at 4 ° C. After storage for 15 hours, the right lung was removed from the cardiopulmonary block, and the remaining left heart lung was connected to a perfusion circuit.
  • the perfusion circuit is housed in a box with a temperature of 37 ° C and a humidity of 100%, and a fresh cardiopulmonary block of the rat is also connected to this circuit.
  • perfusate fresh mixed venous blood of 30 ml obtained from three rats (100 U / heparin) was used, and the port flow rate was 4 ml / min. Perfused underneath for 60 minutes.
  • the left lung after storage for 15 hours was ventilated with 100% oxygen gas under the conditions of a tidal volume of 3 ml and a ventilation rate of 60 times / min.
  • the cardiopulmonary block was ventilated with a mixed gas consisting of 4% oxygen, 8% carbon dioxide and 88% nitrogen under the conditions of a tidal volume of 3 ml and a ventilation rate of 60 / min.
  • a mixed gas consisting of 4% oxygen, 8% carbon dioxide and 88% nitrogen under the conditions of a tidal volume of 3 ml and a ventilation rate of 60 / min.
  • the shunt rate, mean pulmonary artery pressure, and maximum airway pressure in the left heart of the heart were examined. Furthermore, the wet-dry weight ratio of the left heart lung after perfusion for 60 minutes or after cessation of perfusion was determined, and the degree of the occurrence of pulmonary edema was examined from this. Table 1 shows the results.
  • trehalose was contained in the solution of Example 1 and the ET-Kyoto solution but not in the Eurokorin solution, indicating that trehalose also has an organ protective effect. From the above, it was revealed that the preservation solution containing polyphenol has a high organ protection effect, and the preservation solution containing polyphenol and trehalose has a higher organ protection effect.
  • Example 2 solution The cell protecting action of the preservation solution obtained in Example 2 (Example 2 solution) in cryopreservation was examined as follows. For comparison, the cell protection effect of the Cellvation solution was also examined.
  • MDCK a commercially available cell type of dog kidney cells called MDCK (produced by Dainippon Pharmaceutical Co., Ltd., original ATTC strain number CCL-134, survival rate 95%) was prepared, and this was collected at 600 to 800 rpm. Centrifuged for 10 minutes. Subsequently, the supernatant was removed, and a preservation solution was added to the supernatant so as to be 1 ⁇ 10 6 to 1 ⁇ 10 7 ce 11 s / m 1, followed by gentle suspension.
  • each vial was sealed and left at room temperature for 25 minutes. Thereafter, each vial was placed in an insulated container and left in a freezer at 170 ° C. for 2 hours. Next, each vial was transferred to a liquid nitrogen vapor phase, allowed to stand for 24 hours, and then transferred to a liquid nitrogen liquid phase and stored frozen as it was. After 30 days, each vial was removed and quickly thawed in the 37 water bath. After thawing, each vial was wiped with 70% ethanol and left at room temperature for 70 minutes. Then, the cells in each vial were counted to determine the cell viability.
  • A549 cells were cultured in a 24-wel I dish at a concentration of lxl0 5 cells / ml, and after 16 hours, the medium was replaced with a green tea polyphenol-containing medium (green tea polyphenol concentration: 0-0.4 mM) and cultured for 2 hours. . After that, the cells were stimulated with (final concentration 400 iM) and inflammatory cytokine TNF-H (final concentration 20 nM), and the culture medium was collected 1, 3, and 6 hours later. IL-8 concentration in the medium was measured using IL-8 ELISA kit: Pharmingen, OptEIA Human IL-8 Set).
  • A549 cells were cultured in a 60 mm dish at a concentration of 1 ⁇ 10 6 cel ls / ml, and after 24 hours, the medium was replaced with a green tea polyphenol-containing medium (green tea polyphenol concentration: 0.1 ⁇ 2 ⁇ ) and cultured for 2 hours. Then, H 2 Q 2 (final concentration) Stimulation at 400 M) was performed, and after 30 minutes (p38 MAPK) and 60 minutes later UNK), the amount of protein was quantified by Western blotting, and the degree of p38 and JNK activation (phosphorylation) was examined. In preliminary experiments, it was confirmed that p38 MAPK was most strongly activated after 30 minutes and JK was activated 60 minutes after stimulation with. '
  • the medium was replaced with a medium containing green tea (green tea polyphenol concentration: 0-0.4 mM), and the cells were cultured for 8 hours. After that, trypan blue staining was performed, the total number of cells and the number of viable cells were counted, and the cell viability was calculated. (3 ⁇ 5) result As shown in Table 5, green tea polyphenol did not affect the viability of A549 cells at a concentration of 0-0.4 mM. From these results, the safety of green tea polyphenol on alveolar epithelial cells was confirmed.
  • the preservation solution of the present invention has a high protective effect on cells and tissues such as organs, limbs and skin. Therefore, according to the preservation solution of the present invention, the structure and function of cells and tissues can be maintained for a long period of time.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne un fluide de préservation pour cellules et tissus contenant un polyphénol comme ingrédient actif. Ledit fluide peut renfermer du tréhalose. La portée de la pression osmotique préférable se situe entre 270 et 450 Osm/l et la portée du pH préférable entre 7 et 8. Par rapport aux fluides de préservation de la technique antérieure, ce fluide a une meilleure action protectrice et peut maintenir les structures et les fonctions des cellules pour une période de temps prolongée.
PCT/JP2001/005509 2000-07-05 2001-06-27 Fluide de preservation pour cellules et tissus WO2002001952A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001267836A AU2001267836A1 (en) 2000-07-05 2001-06-27 Preservation fluid for cells and tissues
JP2002506588A JP4908718B2 (ja) 2000-07-05 2001-06-27 細胞・組織保存液

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000203891 2000-07-05
JP2000-203891 2000-07-05

Publications (1)

Publication Number Publication Date
WO2002001952A1 true WO2002001952A1 (fr) 2002-01-10

Family

ID=18701239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/005509 WO2002001952A1 (fr) 2000-07-05 2001-06-27 Fluide de preservation pour cellules et tissus

Country Status (3)

Country Link
JP (1) JP4908718B2 (fr)
AU (1) AU2001267836A1 (fr)
WO (1) WO2002001952A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019680A1 (fr) * 2002-08-30 2004-03-11 Mg Pharmacy Inc. Composition permettant de proteger un organe, un tissu ou des cellules et son procede d'utilisation
WO2005072523A2 (fr) * 2004-02-02 2005-08-11 I.M.T. Interface Multigrad Technology Ltd. Materiau biologique et procedes et solutions de conservation de celui-ci
JPWO2003086072A1 (ja) * 2002-03-28 2005-08-18 明治製菓株式会社 臓器保存用組成物および臓器の保存方法
JP2006510640A (ja) * 2002-12-09 2006-03-30 フレセニウス・カビ・ドイチュランド・ゲーエムベーハー 胃腸に投与することができる配合物、およびその使用
JP2006335695A (ja) * 2005-06-02 2006-12-14 Japan Science & Technology Agency 内膜肥厚抑制剤
WO2007015252A3 (fr) * 2005-08-03 2007-08-02 Imt Interface Multigrad Tech Ltd Cellules somatiques utilisees dans la therapie cellulaire
JP2008063235A (ja) * 2006-09-05 2008-03-21 Natl Fedelation Of Agricult Coop Assoc 精液希釈液及び希釈精液の保存方法
JP2010168386A (ja) * 2002-05-10 2010-08-05 Univ Of Miami 細胞および組織のｒｎａおよび形態の保存
JP2010534691A (ja) * 2007-07-30 2010-11-11 ラルフ ローゼル 細胞および／または組織の保護のための物質
US7892726B2 (en) 2004-06-07 2011-02-22 Core Dynamics Limited Method for sterilizing lyophilized eukaryotic anuclear cells with gamma irradiation
WO2011089391A1 (fr) * 2010-01-21 2011-07-28 Cambridge Enterprise Limited Procédés de conservation de cellules de mammifère
WO2011108635A1 (fr) * 2010-03-04 2011-09-09 国立大学法人北海道大学 Agent favorisant le sous-refroidissement
US8196416B2 (en) 2004-02-02 2012-06-12 Core Dynamics Limited Device for directional cooling of biological matter
WO2013047666A1 (fr) * 2011-09-29 2013-04-04 石原産業株式会社 Conservateur pour la conservation à basse température de substances biologiques, et procédé de conservation de substances biologiques à basse température
WO2014010685A1 (fr) * 2012-07-11 2014-01-16 石原産業株式会社 Conservateur pour l'utilisation dans la conservation à basse température de matière biologique, et procédé de conservation de matière biologique à basse température
JPWO2014017267A1 (ja) * 2012-07-25 2016-07-07 国立大学法人大阪大学 組織保存液および組織保存方法
WO2017038805A1 (fr) * 2015-08-31 2017-03-09 石原産業株式会社 Agent de conservation pour organes ou tissus et procédé de conservation pour organes ou tissus
CN107593685A (zh) * 2017-08-11 2018-01-19 同济大学 马尾松树皮提取物在制备移植器官保存液中的应用
JP2019030246A (ja) * 2017-08-08 2019-02-28 学校法人 関西大学 低温障害軽減剤又はネクローシス抑制剤、及び生体の臓器、組織又は細胞の保存方法
WO2023038037A1 (fr) 2021-09-08 2023-03-16 株式会社ガイアバイオメディシン Procédé de traitement des cellules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0393782A (ja) * 1989-08-30 1991-04-18 Pacific Chem Ind Co 活性酸素類から細胞を保護する細胞保護剤
EP0580444A1 (fr) * 1992-07-24 1994-01-26 Hiromi Wada Solution pour l'utilisation dans la transplantation d'organes
EP0845264A1 (fr) * 1996-10-24 1998-06-03 Emil Flachsmann AG Extrait partiel ou total de Camellia sinensis L. non fermenté
EP1057405A1 (fr) * 1999-06-02 2000-12-06 MG Pharmacy Ltd. Agent de stockage pour la préservation des cellules, des tissus ou des organes d'animaux, et procédé correspondant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0393782A (ja) * 1989-08-30 1991-04-18 Pacific Chem Ind Co 活性酸素類から細胞を保護する細胞保護剤
EP0580444A1 (fr) * 1992-07-24 1994-01-26 Hiromi Wada Solution pour l'utilisation dans la transplantation d'organes
EP0845264A1 (fr) * 1996-10-24 1998-06-03 Emil Flachsmann AG Extrait partiel ou total de Camellia sinensis L. non fermenté
EP1057405A1 (fr) * 1999-06-02 2000-12-06 MG Pharmacy Ltd. Agent de stockage pour la préservation des cellules, des tissus ou des organes d'animaux, et procédé correspondant

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003086072A1 (ja) * 2002-03-28 2005-08-18 明治製菓株式会社 臓器保存用組成物および臓器の保存方法
JP4570877B2 (ja) * 2002-03-28 2010-10-27 明治製菓株式会社 臓器保存用組成物および臓器の保存方法
JP2010168386A (ja) * 2002-05-10 2010-08-05 Univ Of Miami 細胞および組織のｒｎａおよび形態の保存
WO2004019680A1 (fr) * 2002-08-30 2004-03-11 Mg Pharmacy Inc. Composition permettant de proteger un organe, un tissu ou des cellules et son procede d'utilisation
EP2269449A3 (fr) * 2002-08-30 2011-03-16 Bmg Incorporated Composition pour la protection et la préservation des organes, tissus ou cellules et utilisation associée
JPWO2004019680A1 (ja) * 2002-08-30 2006-01-05 株式会社ビーエムジー 臓器、組識または細胞の保護および保存のための組成物およびその利用
JP2006510640A (ja) * 2002-12-09 2006-03-30 フレセニウス・カビ・ドイチュランド・ゲーエムベーハー 胃腸に投与することができる配合物、およびその使用
US8196416B2 (en) 2004-02-02 2012-06-12 Core Dynamics Limited Device for directional cooling of biological matter
JP4777908B2 (ja) * 2004-02-02 2011-09-21 コア・ダイナミクス・リミテッド 生物学的材料ならびに生物学的材料の保存のための方法および溶液
US8512941B2 (en) 2004-02-02 2013-08-20 Core Dynamics Limited Biological material and methods and solutions for preservation thereof
JP2007519712A (ja) * 2004-02-02 2007-07-19 アイ．エム．ティー．・インターフェース・マルティグラッド・テクノロジー・リミテッド 生物学的材料ならびに生物学的材料の保存のための方法および溶液
WO2005072523A3 (fr) * 2004-02-02 2005-09-09 Imt Interface Multigrad Tech Ltd Materiau biologique et procedes et solutions de conservation de celui-ci
US7935478B2 (en) 2004-02-02 2011-05-03 Core Dynamics Limited Biological material and methods and solutions for preservation thereof
WO2005072523A2 (fr) * 2004-02-02 2005-08-11 I.M.T. Interface Multigrad Technology Ltd. Materiau biologique et procedes et solutions de conservation de celui-ci
US7892726B2 (en) 2004-06-07 2011-02-22 Core Dynamics Limited Method for sterilizing lyophilized eukaryotic anuclear cells with gamma irradiation
JP2006335695A (ja) * 2005-06-02 2006-12-14 Japan Science & Technology Agency 内膜肥厚抑制剤
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
WO2007015252A3 (fr) * 2005-08-03 2007-08-02 Imt Interface Multigrad Tech Ltd Cellules somatiques utilisees dans la therapie cellulaire
JP4714654B2 (ja) * 2006-09-05 2011-06-29 全国農業協同組合連合会 精液希釈液及び希釈精液の保存方法
JP2008063235A (ja) * 2006-09-05 2008-03-21 Natl Fedelation Of Agricult Coop Assoc 精液希釈液及び希釈精液の保存方法
JP2010534691A (ja) * 2007-07-30 2010-11-11 ラルフ ローゼル 細胞および／または組織の保護のための物質
WO2011089391A1 (fr) * 2010-01-21 2011-07-28 Cambridge Enterprise Limited Procédés de conservation de cellules de mammifère
JP2016204667A (ja) * 2010-03-04 2016-12-08 国立大学法人北海道大学 カテキン型タンニンを含有する不凍性液体及びガラス化液
JPWO2011108635A1 (ja) * 2010-03-04 2013-06-27 国立大学法人北海道大学 過冷却促進剤
JP2015212376A (ja) * 2010-03-04 2015-11-26 国立大学法人北海道大学 タンニンを含有する不凍性液体及びガラス化液
JP5847699B2 (ja) * 2010-03-04 2016-01-27 国立大学法人北海道大学 過冷却促進剤
WO2011108635A1 (fr) * 2010-03-04 2011-09-09 国立大学法人北海道大学 Agent favorisant le sous-refroidissement
WO2013047666A1 (fr) * 2011-09-29 2013-04-04 石原産業株式会社 Conservateur pour la conservation à basse température de substances biologiques, et procédé de conservation de substances biologiques à basse température
WO2014010685A1 (fr) * 2012-07-11 2014-01-16 石原産業株式会社 Conservateur pour l'utilisation dans la conservation à basse température de matière biologique, et procédé de conservation de matière biologique à basse température
JPWO2014017267A1 (ja) * 2012-07-25 2016-07-07 国立大学法人大阪大学 組織保存液および組織保存方法
WO2017038805A1 (fr) * 2015-08-31 2017-03-09 石原産業株式会社 Agent de conservation pour organes ou tissus et procédé de conservation pour organes ou tissus
US11246309B2 (en) 2015-08-31 2022-02-15 Ishihara Sangyo Kaisha, Ltd. Preserving agent for organs or tissue and preservation method for organs or tissue
CN107949277A (zh) * 2015-08-31 2018-04-20 石原产业株式会社 脏器或组织的保存剂和脏器或组织的保存方法
EP3666885A4 (fr) * 2017-08-08 2021-04-21 Shin Nippon Yakugyo Co., Ltd. Agent atténuant les dommages ou inhibiteur de nécrose à basse température, et procédé de conservation d'un organisme, d'un tissu ou d'une cellule vivants
CN110709502A (zh) * 2017-08-08 2020-01-17 新日本药业株式会社 低温损伤减轻剂或者坏死抑制剂以及活体器官、组织或者细胞的保存方法
JP2019030246A (ja) * 2017-08-08 2019-02-28 学校法人 関西大学 低温障害軽減剤又はネクローシス抑制剤、及び生体の臓器、組織又は細胞の保存方法
JP7011117B2 (ja) 2017-08-08 2022-01-26 学校法人 関西大学 低温障害軽減剤又はネクローシス抑制剤、及び生体の臓器、組織又は細胞の保存方法
CN110709502B (zh) * 2017-08-08 2023-11-10 新日本药业株式会社 低温损伤减轻剂或者坏死抑制剂以及活体器官、组织或者细胞的保存方法
CN107593685A (zh) * 2017-08-11 2018-01-19 同济大学 马尾松树皮提取物在制备移植器官保存液中的应用
WO2023038037A1 (fr) 2021-09-08 2023-03-16 株式会社ガイアバイオメディシン Procédé de traitement des cellules
KR20240063899A (ko) 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법

Also Published As

Publication number Publication date
JPWO2002001952A1 (ja) 2004-01-08
JP4908718B2 (ja) 2012-04-04
AU2001267836A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
WO2002001952A1 (fr) Fluide de preservation pour cellules et tissus
US5571801A (en) Plasma expander and blood substitute
CA2066374C (fr) Solutions
AU758703B2 (en) Cryopreservation of human red blood cells
Wicomb et al. Orthotopic transplantation of the baboon heart after 20 to 24 hours’ preservation by continuous hypothermic perfusion with an oxygenated hyperosmolar solution
JPH01246201A (ja) 臓器保存用溶液
WO1990013307A1 (fr) Solution et procede de conservation d'organes
JP2003520859A (ja) 器官および組織保存および低体温血液置換のためのシステム
US5407428A (en) Solutions for use as plasma expanders and substitutes
KR20020059255A (ko) 저온 저장을 개선하기 위한 ＰＥＧ-Ｈｂ를 사용하는 연속심장 관류 보존
JP2006230396A (ja) 細胞保存液
Aeba et al. University of Wisconsin solution for pulmonary preservation in a rat transplant model
Detterbeck et al. Oxygen free radical scavengers decrease reperfusion injury in lung transplantation
US6627393B2 (en) Solutions for use as plasma expanders and substitutes
Soares et al. Comparison between Perfadex and locally manufactured low-potassium dextran solution for pulmonary preservation in an ex vivo isolated lung perfusion model
AU6326198A (en) Organ preservation solution
Lin et al. Donor heart preservation in an empty beating state under mild hypothermia
Olbertz et al. Use of modified Custodiol-N as perfusion solution in ex vivo lung perfusion
Shiraishi et al. Effects of pH and temperature on lung preservation: a study with an isolated rat lung reperfusion model
EP0664953B1 (fr) Composition pour la preservation de greffes de poumon et procédé pour la préservation de greffes de poumon vivantes
KR100304594B1 (ko) 이식용 장기 및 혈액세포 보존제의 조성물
Bando et al. Comparison of euro-collins solution, low-potassium dextran solution containing glucose, and ET-kyoto solution for lung preservation in an extracorporeal rat lung perfusion model
JPH03188001A (ja) 臓器保存用溶液
Suros et al. Twenty-four-hour preservation of the canine heart
Swoboda et al. The influence of verapamil on lung preservation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase